Sotera Health (NASDAQ:SHC) Upgraded to "Buy" at Wall Street Zen

Sotera Health (NASDAQ:SHC - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other research firms have also recently commented on SHC. The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and upped their price objective for the company from $14.00 to $17.00 in a report on Monday, May 5th. Barclays reduced their price objective on Sotera Health from $15.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 24th. Finally, Piper Sandler lowered their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.00.

Sotera Health Stock Up 3.0%

Shares of SHC traded up $0.33 during trading hours on Friday, hitting $11.45. The company had a trading volume of 1,656,375 shares, compared to its average volume of 1,229,748. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The company has a market capitalization of $3.25 billion, a PE ratio of 143.14 and a beta of 1.81. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55. The company's fifty day moving average price is $12.03 and its two-hundred day moving average price is $12.35.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The firm had revenue of $254.52 million for the quarter, compared to analyst estimates of $245.56 million. Sotera Health had a return on equity of 41.08% and a net margin of 2.24%. Sotera Health's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 earnings per share. As a group, equities analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sotera Health

A number of large investors have recently added to or reduced their stakes in SHC. Quarry LP bought a new position in Sotera Health in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd raised its stake in Sotera Health by 3,690.1% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company's stock valued at $31,000 after purchasing an additional 2,620 shares during the period. Summit Securities Group LLC acquired a new stake in Sotera Health during the 1st quarter worth about $67,000. Farther Finance Advisors LLC grew its holdings in shares of Sotera Health by 4,881.9% during the 1st quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company's stock valued at $70,000 after acquiring an additional 6,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Sotera Health by 37.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after purchasing an additional 1,640 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.